Objective To identify the risk factors for predicting the dynamic progression of COVID-19. Methods A total of 2321 eligible patients were included in this study from February 4 to April 15, 2020. Two illness conditions, including mild/moderate (M/M) subtype to severe/critical (S/C) and S/C to fatality, were classified. Clinical message was collected and compared, respectively. Kaplan–Meier method, Cox regression model and risk score system were used to predict disease progression in S/C COVID-19. Results A total of 112 of 1761 patients with M/M subtype were progressors (P) and 1649 non-progressors (NP). Increasing disease progression associated with higher levels of neutrophils count (HR=1.958, 95% CI=1.253–3.059, P =0.003), CK (HR=2.203, 95% CI=1.048–4.632, P =0.037), LDH (HR=3.309, 95% CI=2.083–5.256, P <0.001) and CRP (HR=2.575, 95% CI=1.638–4.049, P <0.001), and lower level of lymphocytes count (HR=1.549, 95% CI=1.018–2.355, P =0.041), as well as total lesion volume ratio greater than ≥10% (HR=2.286, 95% CI=1.451–3.601, P <0.001) on admission. In progression to fatality, 56 of the 672 S/C cases died and 616 survived. Increasing fatality associated with lower level of lymphocytes count (HR:2.060, 95% CI:1.000–4.242, P =0.050), higher levels of BUN (HR:2.715, 95% CI:1.539–4.790, P <0.001), CK-MB (HR:3.412, 95% CI:1.760–6.616, P <0.001), LDH (HR:5.578, 95% CI:2.317–13.427, P <0.001), and PT (HR:3.619, 95% CI:2.102–6.231, P <0.001). Furthermore, high risk of neutrophils count, lymphocytes count, CK, LDH, CRP, and total lesion volume ratio was powerfully correlated with the incidence of progression to S/C in patients with NS COVID-19 and high odds of lymphocytes count, BUN, CK-MB, LDH, and PT were significantly associated with death in patients with S/C COVID-19. In addition, the progression and mortality rates increased with increasing risk scores. Conclusion Elevated LDH level and lymphopenia were independent predictors for COVID-19 sustainable management in classifying non-severe patients who progressed to severe condition and identifying S/C patients who deteriorated to fatal outcomes as well. Total lesion volume ratio ≥10% may provide early predictive evidence with COVID-19 patients at high risk of developing into S/C to improve prognosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.